Overview

This trial is active, not recruiting.

Condition primary progressive multiple sclerosis
Treatments laquinimod, placebo
Phase phase 2
Sponsor Teva Pharmaceutical Industries
Start date January 2015
End date September 2017
Trial size 374 participants
Trial identifier NCT02284568, 2014-001579-30, TV5600-CNS-20006

Summary

This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Experimental)
once daily oral dose.
laquinimod
Laquinimod 0.6 mg, 1.5 mg
(Experimental)
once daily oral dose NOTE- As of January 2016, this arm has been discontinued.
laquinimod
Laquinimod 0.6 mg, 1.5 mg
(Placebo Comparator)
once daily oral dose
placebo
Placebo

Primary Outcomes

Measure
Percent brain volume change (PBVC)
time frame: 48 weeks

Secondary Outcomes

Measure
Time to confirmed disability progression (CDP)
time frame: 48 weeks
Change from baseline in timed 25 foot walk
time frame: Baseline, Week 48
Number of new T2 brain lesions
time frame: 48 weeks

Eligibility Criteria

Male or female participants from 25 years up to 55 years old.

Inclusion Criteria: 1. Patients must have a confirmed and documented PPMS diagnosis as defined by the 2010 Revised McDonald criteria 2. Baseline magnetic resonance imaging (MRI) showing lesions consistent with PPMS in either or both brain and spinal cord 3. Patients must have an Expanded Disability Status Scale (EDSS) score of 3 to 6.5, inclusive, at both screening and baseline visits 4. Documented evidence of clinical disability progression in the 2 years prior to screening. 5. Functional System Score (FSS) of > or equal 2 for the pyramidal system or gait impairment due to lower extremity dysfunction 6. Patients must be between 25 to 55 years of age, inclusive 7. Women of child-bearing potential must practice an acceptable method of birth control for 30 days before taking the study drug, and 2 acceptable methods of birth control during all study duration and until 30 days after the last dose of treatment is administered. 8. Patients must sign and date a written informed consent prior to entering the study. 9. Patients must be willing and able to comply with the protocol requirements for the duration of the study. Exclusion Criteria: 1. Patients with history of any multiple sclerosis (MS) exacerbations or relapses, including any episodes of optic neuritis. 2. Progressive neurological disorder other than PPMS. 3. Any MRI record showing presence of cervical cord compression. 4. Baseline MRI showing other findings (including lesions that are atypical for PPMS) that may explain the clinical signs and symptoms. 5. Relevant history of vitamin B12 deficiency. 6. Positive human T-lymphotropic virus Type I and II (HTLV-I/II) serology. 7. Use of experimental or investigational drugs in a clinical study within 24 weeks prior to baseline. Use of a currently marketed drug in a clinical study within 24 weeks prior to baseline would not be exclusionary, provided no other exclusion criteria are met. 8. Use of immunosuppressive agents, or cytotoxic agents, including cyclophosphamide and azathioprine within 48 weeks prior to baseline. 9. Previous treatment with fingolimod (GILENYA®, Novartis), dimethyl fumarate (TECFIDERA®, Biogen Idec Inc), glatiramer acetate (COPAXONE®, Teva), interferon-β (either 1a or 1b), intravenous immunoglobulin, or plasmapheresis within 8 weeks prior to baseline. 10. Use of teriflunomide (AUBAGIO®, Sanofi) within 2 years prior to baseline, except if active washout (with either cholestyramine or activated charcoal) was done 2 months or more prior to baseline. 11. Prior use of monoclonal antibodies ever, except for: 1. natalizumab (TYSABRI®, Biogen Idec Inc), if given more than 24 weeks prior to baseline AND the patient is John Cunningham (JC) virus antibody test negative (as per medical history) 2. rituximab, ocrelizumab, or ofatumumab, if B cell count (CD19, as per medical history) is higher than 80 cells/μL 12. Use of mitoxantrone (NOVANTRONE®, Immunex) within 5 years prior to screening. Use of mitoxantrone >5 years before screening is allowed in patients with normal ejection fraction and who did not exceed the total lifetime maximal dose. 13. Previous use of laquinimod. 14. Chronic (eg, more than 30 consecutive days or monthly dosing, with the intent of MS disease modification) systemic (intravenous, intramuscular or oral) corticosteroid treatment within 8 weeks prior to baseline. 15. Previous use of cladribine or alemtuzumab (LEMTRADA®, Sanofi). 16. Previous total body irradiation or total lymphoid irradiation. 17. Previous stem cell treatment, cell-based treatment, or bone marrow transplantation of any kind. 18. Patients who underwent endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI) within 12 weeks prior to baseline. 19. Use of moderate/strong inhibitors of cytochrome P450 (CYP) 3A4 within 2 weeks prior to baseline. 20. Use of inducers of CYP3A4 within 2 weeks prior to baseline. 21. Pregnancy or breastfeeding. 22. Serum levels ≥3× upper limit of the normal range (ULN) of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at screening. 23. Serum direct bilirubin which is ≥2×ULN at screening. 24. Patients with a clinically significant or unstable medical or surgical condition that (in the opinion of the Investigator) would preclude safe and complete study participation, as determined by medical history, physical examinations, electrocardiogram (ECG), laboratory tests or chest X-ray. 25. A known history of hypersensitivity to gadolinium (Gd). 26. Glomerular filtration rate (GFR) < or equal 60 mL/min at screening visit. 27. Inability to successfully undergo MRI scanning, including claustrophobia. 28. Known drug hypersensitivity that would preclude administration of laquinimod, such as hypersensitivity to mannitol, meglumine or sodium stearyl fumarate.

Additional Information

Official title A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) Phase 2
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Teva Pharmaceutical Industries.